RXRX — Recursion Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$3.38
+$0.05 (+1.65%)
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ. It is led by Najat Khan Ph.D., based in 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101, with about 600 employees. Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Latest reported RXRX revenue for 2025-09-30 was $5.2M. Net income was -$162.3M. Revenue was down 73.1% from 2025-06-30 to 2025-09-30. RXRX currently screens at market cap $1.75B.
Use this RXRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RXRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RXRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Recursion Pharmaceuticals Inc even when a live quote feed is slow.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Key Statistics
Market Cap
$1.75B
Volume
19.21M
Previous Close
$3.25
Day Range
$3.26 – $3.59
P/B Ratio
1.70
EPS
-$1.69
Revenue
$58.84M
Net Income
-$463.66M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+32.0%
Profit Margin
-788.0%
Employees
600
RXRX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $58.84M | $44.58M | $39.84M | $10.18M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$463.66M | -$328.07M | -$239.48M | -$186.48M |
| EPS (Diluted) | -$1.69 | -$1.58 | -$1.36 | -$1.49 |
Total Assets
$1.45B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$594.35M
Operating Cash Flow
-$359.17M
Free Cash Flow
$0.00
Recursion Pharmaceuticals Inc Company Information
- CEO, President & Director
- Najat Khan Ph.D.
- Headquarters
- 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101
- Website
- www.recursion.com
- Phone
- 385 269 0203
- IPO / Founded
- 2021-04-16
- Sector
- Healthcare
- Industry
- Biotechnology